Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
-
HRSA Revises RWHAP Policy Notice on Eligibility Determinations
In October 2021, HRSA's HIV/AIDS Bureau revised its client eligibility and recertification policy for the Ryan White HIV/AIDS Program.
News Article updated on 11/02/2021 -
HRSA Releases New Fact Sheets on RWHAP Clients
Ten fact sheets on client populations getting care from the Ryan White HIV/AIDS Program (RWHAP) a
News Article updated on 06/30/2021 -
Elevating Consumer Voices
Building consumer leadership skills and strategies to help ensure and amplify consumer input into PC/PB activities.Resource updated 01/05/2024
-
Making Room at the Table: Recruiting, Retaining, and Engaging Youth and Young Adults
Improving reflectiveness and representation by working to build up youth and young adult involvement in PC/PBs.Resource updated 01/05/2024
-
Use of Social Media and Mobile Technology as Essential Tools for EHE
Strategies to engage hard-to-reach youth and young adults through use of social media and related technologies.Resource updated 03/15/2023
-
Online Course on Integrated Planning
-
ADR Town Hall
ADAP discussion session on the 2022 ADR submission process.Resource updated 08/16/2023
-
Ending the HIV Epidemic through Innovations in Rapid ART
Review of innovative Rapid ART strategies in diverse settings.Resource updated 03/15/2023
-
Overview of the Ryan White HIV/AIDS Program Part A Planning Council Cycle
Overview of each component of the Ryan White HIV/AIDS Program (RWHAP) Part A planning cycle.Resource updated 01/05/2024
-
Broward County HIV Health Services Planning Council
-
Fillable CY 2022 – 2026 CDC DHP and HRSA HAB Integrated Prevention and Care Plan Guidance Checklist
Checklist required in the submission of the Integrated Plans for 2022-2026.Resource updated 09/19/2023
-
Crosswalk of the Integrated HIV Prevention and Care Plan Guidance (CY 2016-2021 and CY 2022-2026) and the Ending the HIV Epidemic in the U.S. Program Guidance
Crosswalk of the required components of the 2022-2026 Integrated HIV Prevention and Care Plan with the 2016-2021 Integrated HIV Prevention and Care Plans and the EHE Planning Program Guidance.Resource updated 09/19/2023
-
HIV 101: Fundamentals of HIV Pathogenesis, Antiretroviral Therapy Initiation, & Primary Care for PWH
Session for clinicians new to the field of HIV or those looking for a review on the core principles of HIV management, including pathogenesis of HIV infection, mechanism of action of antiretroviral drugs, initiating antiretroviral therapy, and primary care for people with HIV.Resource (Conference Presentation) updated 09/14/2023
-
Integrated HIV Prevention and Care Plan: Planning Requirements
Outline of the planning requirements for RWHAP Parts A and B recipients and all DHAP-funded state and local health departments as described in the Integrated HIV Prevention and Care Plan Guidance, Including the SCSN, CY 2022-2026.Resource updated 08/03/2023
-
Responsibilities and Expectations of Individual Members - How the PC/PB can Support Them
This resource for new planning council members helps orient them to their roles and duties as HIV community planners.Resource updated 04/18/2024
-
ADR In Focus: Partial Premiums
Full versus partial premiums for ADR client-level data reporting and reporting strategies.Resource updated 09/14/2023
-
New Investigational ART Drugs and Strategies
Review of investigational drugs in phase III trials (as of 2021: Islatravir, Lenacapravir, GSK 3640254/aka GSK “254) and how these investigational agents might be used in treatment in the future. Also, review of long-acting injectables.Resource (Conference Presentation) updated 09/14/2023
-
Managing Polypharmacy and Drug-Drug Interactions
Review of common mechanisms for drug interactions with contemporary ART; therapeutic classes of drugs with high interaction potential with ART; distinctions between oral vs intramuscular cabotegravir/rilpivirin interactions; and comparison of the clinical pharmacology and drug interaction potential of tenofovir alafenamide vs tenofovir disoproxilfumarate.Resource (Conference Presentation) updated 09/14/2023
-
Cases From the Clinic(ians): Antiretroviral Therapy Cases and Panel Discussion
Insights for clinicians on selecting antiretroviral therapy and/or managing patients who: are starting initial therapy; are Elite Controllers; have InSTI-associated weight gain; have persistent low-level viremia; have a discordant CD4+ count response to ART; have ‘Blips’; and/or are aging.Resource (Conference Presentation) updated 04/08/2024